Business Wire

CA-EVIDATION

16.11.2023 15:01:58 CET | Business Wire | Press release

Share
Evidation Selected by Our Future Health as Participant Platform for UK’s Largest Health Research Program

Evidation — the company creating new ways to measure and improve health in everyday life — today announced a landmark partnership with Our Future Health, a national health research initiative and collaboration between the UK’s National Health Service (NHS), public health agencies, non-profits, and leading life sciences companies. Our Future Health will deploy Evidation’s enterprise digital health engagement and measurement platform to conduct a multi-year, longitudinal research program for up to five million participants across the UK.

“Evidation and Our Future Health believe that deeply understanding individuals' everyday health experiences can accelerate discoveries that will transform health," said Christine Lemke, Co-founder and CEO of Evidation. "Together, with the participation of millions of volunteers across the UK, we will enable research that can advance more inclusive and effective ways to prevent, detect, and treat disease."

“Our Future Health aims to be a world-leading resource for health research,” said Dr Raghib Ali OBE, Chief Executive of Our Future Health. “Evidation has extensive expertise measuring and characterizing health in everyday life and engaging people at scale. This, combined with their experience in deploying large research and engagement programs and their shared commitment to the highest standards of data protection and user privacy, makes them the ideal partner for Our Future Health.”

Our Future Health is bringing together up to five million people to develop new ways to prevent, detect and treat diseases. To achieve this, Our Future Health will recruit a diverse and inclusive cohort of people across the UK who have consented to participate. The program population accounts for almost 10% of the UK’s adult population of over 53 million people. Evidation’s technology will power the digital experience, including a participant-facing app and technology infrastructure, that makes this massive research initiative possible. This new digital experience will be developed in the coming months.

Evidation’s platform is the technology layer that powers health research and engagement programs for some of the world’s leading healthcare organizations. Evidation makes it possible to harness real-world data — including wearables and survey data — to deeply understand health experiences rapidly and longitudinally, in large populations. Refined over a decade, Evidation’s measurement and engagement platform helps capture health data from outside the clinic and rewards participants for taking healthy actions.

About Evidation

Evidation creates new ways to measure and improve health in everyday life — making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe. Learn more at www.evidation.com.

About Our Future Health

Our Future Health is a collaboration between the public, private and charity sectors. It aims to be the UK’s largest health research program, bringing people together to develop new ways to prevent, detect and treat disease.

Our Future Health is committed to the highest standards, policies and processes that protect participants’ confidentiality, whilst maximizing the opportunity to help researchers to tackle serious diseases. Participants’ data is de-identified and held securely in trusted research environments that meet strict security criteria. There is a robust and transparent access process to ensure appropriate research access to Our Future Health data and samples for registered researchers. All researchers are held to the same standards.

Our Future Health is a member of the UK Health Data Research Alliance, the independent alliance of leading healthcare and research organizations establishing best practice for the ethical use of UK health data for research at scale.

Our Future Health is a company limited by guarantee registered in England and Wales (number 12212468) and a charity registered with the Charity Commission for England and Wales (charity number 1189681) and OSCR, Scottish Charity Regulator (charity number SC050917).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116712663/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NetApp Helps Customers Accelerate Adoption of Latest VMware Cloud Foundation Innovations2.9.2026 22:30:00 CEST | Press release

NetApp solutions validated to support VCF 9.1, giving mutual customers access to a modern private cloud with enterprise-grade data management, cyber resilience, and cost-efficient scaling NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, announced new capabilities in NetApp ONTAP® have been tested and validated to support VMware Cloud Foundation (VCF) 9.1, giving customers an optimized and secure data infrastructure foundation for their private and hybrid clouds. By combining the advanced capabilities of VCF 9.1 with cost-effective and enterprise data management with built-in security features from NetApp, including safeguarding data against ransomware attacks with rapid recovery, mutual customers can lower costs and accelerate the deployment of their AI software into production. VMware Cloud Foundation 9.1 provides enterprises with a unified private cloud platform for running both traditional and modern workloads. NetApp's solutions are tested and validated to suppo

Venture Global Announces Closing of $3,000,000,000 364-Day Senior Secured Revolving Credit Facility2.9.2026 22:30:00 CEST | Press release

Venture Global, Inc. (“Venture Global”) announced today that its subsidiary Venture Global LNG, Inc. (“VGLNG”) has entered into a new, $3,000,000,000 364-day revolving credit facility (the “Facility”). Venture Global expects to use the proceeds from borrowings under the Facility for general corporate purposes of VGLNG and its subsidiaries, including to fund certain project costs for the CP2 and Plaquemines bolt-on expansions prior to their respective FIDs. Bank of America, N.A. served as Coordinating Lead Arranger and Sole Bookrunner and will also serve as Administrative Agent. BBVA, Goldman Sachs, ING, J.P. Morgan, Mizuho, MUFG, NBC, RBC, Scotia, SMBC, U.S. Bank, and Wells Fargo served as Coordinating Lead Arrangers and Barclays, Santander, and Deutsche Bank served as Joint Lead Arrangers. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Vent

Invivoscribe Begins Commercial Shipments of PrepQuant™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing2.9.2026 21:31:00 CEST | Press release

New automated platform is designed to improve the quality, efficiency, and consistency of DNA extraction and concentration from large-volume blood and plasma samples, supporting downstream assays capable of detecting disease-associated signals at MRD sensitivity levels. Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial shipments of the PrepQuant™ System have begun in North America. First unveiled at the American Association for Cancer Research Annual Meeting in April 2026, PrepQuant is now being delivered to customers, marking the platform's progression from development and validation into commercial deployment. The commercial milestone extends Invivoscribe's capabilities into laboratory instrumentation and addresses a critical bottleneck in highly sensitive molecular testing: efficiently recovering, concentrating, and quantifying DNA from larger blood and plasma inputs. PrepQuant is assay agnostic, de

C.H. Guenther Opens Centre of Excellence in Coventry, UK to Accelerate Bakery Innovation and Support Future Manufacturing Growth Across UK and Europe2.9.2026 18:00:00 CEST | Press release

C.H. Guenther & Son LLC (“C.H. Guenther” or “CHG”), a leading food manufacturer, has opened a new Centre of Excellence (the “Centre”) at its flagship Coventry bakery, creating a dedicated innovation and customer collaboration hub designed to accelerate the development of premium bakery products across the UK and Europe. The new facility has been designed to support CHG’s customers including leading global quick service restaurants, foodservice operators and retailers as they develop, test and refine new bakery products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902696890/en/ The purpose-built, 172-square-metre Centre of Excellence brings together a commercial-scale bakery, customer demonstration kitchen, sensory evaluation facilities, innovation suite and dedicated collaboration spaces in one specialized location. Designed to support and accelerate product development from concept through to commercial manufacturing,

Record Asset Management Enters New Phase of Growth2.9.2026 17:35:00 CEST | Press release

Record Asset Management GmbH (“RAM”), a subsidiary of London-listed Record plc (“Record” or the “Group”), is pleased to announce that it is now operating cashflow positive, thereby marking a transition from its investment phase into a growth business within the Group, and a significant milestone towards sustainable profitability. RAM is the European asset management arm of Record, the London-listed specialist investment group managing USD 122 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. RAM was established as a sister company to Record’s core currency business and obtained its BaFin license in 2022. RAM has grown rapidly in the last two years and has developed into a diversified private markets platform with dedicated infrastructure e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye